No Data
No Data
Atea Pharmaceuticals Announces Results From Phase 2 Study of Bemnifosbuvir
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
Atea Pharmaceuticals Says Strategic Alternatives Process 'Ongoing'
Atea Pharmaceuticals Appoints Howard Berman to Board of Directors
Atea Pharmaceuticals: Radoff-JEC Group Has Agreed to Vote All of Shrs It Collectively Owns in Favor of Each of Atea's Bd Nominees at 2025 Annual Meeting >AVIR
Atea Pharmaceuticals Enters Into Agreement With Bradley L. Radoff and Michael Torok >AVIR